Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Rheumatoid Arthritis Healthy General: Healthy women, or women with RA, 18-55 year old, with a history of regular menses or who are perimenopausal, have a BMI less than 30, able to provide informed consent to all aspects of the study after full information is provided. Women must have a negative pregnancy test at screening. Study participants will be allowed to continue taking medications for chronic, stable conditions, such as hypertension and hypercholesteremia, while in the study for RA Patients: Active RA as defined by 9 tender and 6 swollen joints; ESR greater than 35 mm/hr OR CRP greater than 2.0 mg/dL; and, morning stiffness greater than 45 min. Actively menstruating with a normal estrogen level or who are perimenopausal. Women must be practicing, or willing to practice, an acceptable method of birth control that does not involve use of prescription or OTC estrogen/progesterone preparations during the two weeks prior to screening. Acceptable means of contraception abstinence, barrier methods with spermicides, intrauterine devices (IUD's) or surgical sterilization. (phase 2 of the study only) Current use of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or hydroxychloroquine are permitted. Drug doses must have been stable for at least one month prior to enrollment, and must be held constant during the study unless toxicity requires dose reduction. Past use of a disease modifying agent (DMARD) such as methotrexate, sulfasalazine and cyclosporine is allowed  General: Patients or control subject will be excluded if they exhibit any medical condition that has the potential of placing the candidate at unnecessary risk during the study. Additionally, patients with impaired renal, hepatic, cardiovascular or endocrine-metabolic function, or any immunodeficiency syndrome including HIV infection, will be excluded Use of systemic corticosteroids in the two weeks before screening and study entry. Women with a history of cancer, with the exception of limited, resolved skin cancer. Women who are menopausal. Clinical menopause is defined as the absence of spontaneous menses during the preceding 12 months. Pregnant women or women who are nursing. Use of prescription or OTC estrogen/progesterone preparations during the two weeks prior to screening The patient or control subject has received any investigational drug within 30 days of the start of the study. History of autoimmune endocrinopathy. Serious medical illnesses or abnormal laboratory values that would, in the opinion of the P.I., preclude study participation For RA Patients: BMI greater than or equal to 30. Active infection or other contraindication to use of an anti-TNF agent (phase 2 of the study only). History of untreated tuberculosis, or of a positive PPD without completion of adequate treatment. (phase 2 of the study only) Live vaccinations in the 3 months prior to study (phase 2 of the study only)